Sionna Therapeutics is trading 8.24% up at $5.46, following a highly volatile rebound after the August 10 Phase 2a trial failure.
- The company discontinued SION-719 as an add-on cystic-fibrosis treatment after it failed its key endpoint, with a -1.0 mmol/L placebo-adjusted sweat-chloride change and p=0.7.
- No new company-specific catalyst clearly explains the August 12 gain.
- Broader markets are modestly positive, while heightened volatility and recent analyst downgrades remain relevant trading context.